Filtered By:
Condition: Hemorrhagic Stroke
Drug: Warfarin

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 721 results found since Jan 2013.

Net Clinical Benefit of Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation: A Subgroup Analysis of J-ROCKET AF
Conclusion: Analysis of the NCB supports that rivaroxaban therapy provides clinical benefit for Japanese patients with AF.
Source: Journal of Stroke and Cerebrovascular Diseases - November 4, 2013 Category: Neurology Authors: Shinichiro Uchiyama, Masatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, Shin-ichi Momomura, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Hitoshi Ueda, Kazuma Iekushi, Satoshi Yamanaka, Masahiro Tajiri, J-ROCKET AF Study Tags: Original Articles Source Type: research

Incidence of Symptomatic Hemorrhage in Patients With Lobar Microbleeds Clinical Sciences
Conclusions— Patients presenting with isolated lobar microbleeds on MRI have a genetic, neuroimaging, and hemorrhagic risk profile suggestive of severe CAA pathology. They have a substantial risk of incident ICH, potentially affecting decisions regarding anticoagulation in clinical situations.
Source: Stroke - July 28, 2014 Category: Neurology Authors: van Etten, E. S., Auriel, E., Haley, K. E., Ayres, A. M., Vashkevich, A., Schwab, K. M., Rosand, J., Viswanathan, A., Greenberg, S. M., Gurol, M. E. Tags: Acute Cerebral Hemorrhage, Computerized tomography and Magnetic Resonance Imaging, Intracerebral Hemorrhage, Risk Factors for Stroke, Anticoagulants Clinical Sciences Source Type: research

Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin Clinical Sciences
Conclusions— In this sample of AF patients with ICB on oral anticoagulants, dabigatran was not associated with higher in-hospital mortality compared with warfarin. Hence, reluctance to use dabigatran because of a lack of approved reversal agents is not supported by our results.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Alonso, A., Bengtson, L. G. S., MacLehose, R. F., Lutsey, P. L., Chen, L. Y., Lakshminarayan, K. Tags: Cerebrovascular disease/stroke, Coumarins, Other anticoagulants, Arrhythmias, clinical electrophysiology, drugs, Anticoagulants Clinical Sciences Source Type: research

Rivaroxaban and Apixaban Reduce Hemorrhagic Transformation After Thrombolysis by Protection of Neurovascular Unit in Rat Basic Sciences
Conclusions— This study shows a lower risk of intracerebral hemorrhage after tissue-type plasminogen activator treatment in rats with ischemic stroke that are pretreated with rivaroxaban and apixaban compared with pretreatment with warfarin. Reducing neurovascular dissociation by rivaroxaban and apixaban compared with warfarin could partly explain a reduction in hemorrhagic complications reported in clinical studies.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Kono, S., Yamashita, T., Deguchi, K., Omote, Y., Yunoki, T., Sato, K., Kurata, T., Hishikawa, N., Abe, K. Tags: Animal models of human disease Basic Sciences Source Type: research

Characteristics of Intracerebral Hemorrhage During Rivaroxaban Treatment: Comparison With Those During Warfarin Brief Reports
Conclusions— Rivaroxaban-associated ICH occurs in patients at high risk for major bleeding. However, they had a relatively small hematoma, no expansion of hematoma, and favorable functional and vital outcomes compared with warfarin-associated ICH.
Source: Stroke - August 25, 2014 Category: Neurology Authors: Hagii, J., Tomita, H., Metoki, N., Saito, S., Shiroto, H., Hitomi, H., Kamada, T., Seino, S., Takahashi, K., Baba, Y., Sasaki, S., Uchizawa, T., Iwata, M., Matsumoto, S., Osanai, T., Yasujima, M., Okumura, K. Tags: Other anticoagulants, Acute Cerebral Hemorrhage Brief Reports Source Type: research

Incidence, Mortality, and Risk Factors for Oral Anticoagulant–associated Intracranial Hemorrhage in Patients with Atrial Fibrillation
Warfarin, a vitamin K epoxide reductase inhibitor, is the oral anticoagulant most commonly used to reduce the risk of stroke in patients with atrial fibrillation (AF). Warfarin has proved to be efficacious for this purpose in multiple clinical trials. However, warfarin use is laborious and associated with an increased risk of intracranial hemorrhage (ICH). Various factors increase the risk of warfarin-related ICH, including older age, intensity of anticoagulation, hypertension, and history of cerebrovascular disease.
Source: Journal of Stroke and Cerebrovascular Diseases - October 29, 2014 Category: Neurology Authors: Rebbeca Grysiewicz, Philip B. Gorelick Tags: Review Article Source Type: research

Setting up the Right Scenarios for Cost-Effectiveness Analysis: An Example with Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients in China
Warfarin, the standard oral anticoagulant for stroke prevention in patients with atrial fibrillation (AF), is associated with frequent international normalized ratio (INR) monitoring and increased hemorrhagic risk. About 50% of European and American AF patients received warfarin nevertheless. Dabigatran, a novel oral anticoagulant, had been compared to warfarin to demonstrate its cost-effectiveness in developed countries. However, these economic evaluations couldn’t be applied to China setting. Despite treatment guidelines, warfarin use was conservative in China accounting for only 2.7% AF patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: Y. Wan, Z.G. Lu, F. Chen, J. Chen Source Type: research

Build Model with Asia Pacific Region in Mind: Modeling INR Control in a Cost-Effectiveness Model for Stroke Prevention in Atrial Fibrillation Patients
Patients, physician behaviors, and health systems differ across regions. Models without features to account for heterogeneity can’t be readily adapted in AP region. Warfarin, the standard care for stroke prevention in atrial fibrillation patients, requires routine monitoring of International Normalized Ratio (INR). Below or above the target range (2.0-3.0) increases ischemic or hemorrhagic events, respectively. Time in therapeutic range (TTR) determines therapeutic effectiveness. INR monitoring and increased hemorrhagic risk created barriers for broad effective warfarin use in AP region.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: J. Chen, Y. Wan, F. Chen, Z.G. Lu Tags: Research on Methods - Modeling Methods Source Type: research

Letter by Feng et al Regarding Article, "Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control" Letters to the Editor
Source: Stroke - February 23, 2015 Category: Neurology Authors: Feng, X., Huan, Y., Lv, Y. Tags: Secondary prevention, Acute Cerebral Infarction Letters to the Editor Source Type: research

Response to Letter Regarding Article, "Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control" Letters to the Editor
Source: Stroke - February 23, 2015 Category: Neurology Authors: Chan, P.-H., Hai, J. J., Siu, C.-W. Tags: Coumarins Letters to the Editor Source Type: research

Validation of the 9-Point and 24-Point Hematoma Expansion Prediction Scores and Derivation of the PREDICT A/B Scores Clinical Sciences
Conclusions— The 9- and 24-point expansion scores demonstrate acceptable discrimination in an independent multicenter cohort; however, calibration was suboptimal for the 9-point score. The PREDICT A score showed improved discrimination for HE prediction but requires independent validation.
Source: Stroke - October 26, 2015 Category: Neurology Authors: Huynh, T. J., Aviv, R. I., Dowlatshahi, D., Gladstone, D. J., Laupacis, A., Kiss, A., Hill, M. D., Molina, C. A., Rodriguez-Luna, D., Dzialowski, I., Silva, Y., Kobayashi, A., Lum, C., Boulanger, J.-M., Gubitz, G., Bhatia, R., Padma, V., Roy, J., Kase, C. Tags: Acute Cerebral Hemorrhage, Angiography, Computerized tomography and Magnetic Resonance Imaging, Intracerebral Hemorrhage, Anticoagulants Clinical Sciences Source Type: research

Safety of Mechanical Thrombectomy for Acute Ischemic Stroke in Patients on Novel Oral Anticoagulants (P1.196)
Conclusion: Patients on NOAC undergoing mechanical thrombectomy show a trend towards increased sICH compared to the warfarin group. This may warrant larger studies of safety of mechanical thrombectomy in the presence of NOACs.Disclosure: Dr. Sharma has nothing to disclose. Dr. Atchaneeyasakul has nothing to disclose. Dr. Ziayee has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Guada has nothing to disclose. Dr. Khandelwal has nothing to disclose. Dr. Ramdas has nothing to disclose. Dr. Yavagal has received personal compensation for activities with Covidien/evV3 as a consultant and Steering Committee Member.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Sharma, P., Atchaneeyasakul, K., Ziayee, H., Malik, A., Guada, L., Khandelwal, P., Ramdas, K., Yavagal, D. Tags: Acute Endovascular Therapy: Outcomes and Safety Source Type: research

Noncontrast Computed Tomography Hypodensities Predict Poor Outcome in Intracerebral Hemorrhage Patients Clinical Sciences
Conclusions— The presence of noncontract CT hypodensities at baseline independently predicts poor outcome and comes as a useful and widely available addition to our ability to predict ICH patients’ clinical evolution.
Source: Stroke - September 25, 2016 Category: Neurology Authors: Boulouis, G., Morotti, A., Brouwers, H. B., Charidimou, A., Jessel, M. J., Auriel, E., Pontes-Neto, O., Ayres, A., Vashkevich, A., Schwab, K. M., Rosand, J., Viswanathan, A., Gurol, M. E., Greenberg, S. M., Goldstein, J. N. Tags: Computerized Tomography (CT), Prognosis, Mortality/Survival, Cerebrovascular Disease/Stroke, Intracranial Hemorrhage Clinical Sciences Source Type: research

Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation —a cohort study in primary care
ConclusionsIn this clinical setting, we found no evidence pointing to an increased risk of HS with antithrombotic treatment.
Source: European Journal of Clinical Pharmacology - November 7, 2016 Category: Drugs & Pharmacology Source Type: research

The clinical management of cerebral venous sinus thrombosis. a uk survey
Conclusion Overall respondents were confident in the use of heparin for the treatment of CVST. Respondents used LMWH predominantly, in keeping with EFNS guidance, yet in contrast to a previous European survey.1
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Lavin, T., Punter, M., Holland, M. Tags: Stroke ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research